Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Prolonged survival and durable responses in several late-stage cancers such as melanoma and lung cancer have been made possible with the use of immune checkpoint inhibitors targeting the programmed cell-death protein 1 (PD-1) or its ligand PD-L1. While it is prudent to focus on the unprecedented and...
| Հիմնական հեղինակներ: | , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
MDPI AG
2022-11-01
|
| Շարք: | Immuno |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.mdpi.com/2673-5601/2/4/41 |